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Abstract
Background: To date, there is no consensus on the utility of screening procedures for the early
detection of endometrial cancer. The value of transvaginal ultrasound for screening of
asymptomatic endometrial cancer has been discussed controversially. This study was conducted to
evaluate whether asymptomatic patients with endometrial cancer have a better prognosis than
symptomatic patients with endometrial cancer diagnosed after postmenopausal bleeding.
Methods: In the present multi-center study, the effect of the presence of postmenopausal bleeding
on prognosis was evaluated retrospectively in 605 patients with endometrial cancer using patients'
files. 543 patients (133 patients were asymptomatic, 410 patients were symptomatic) with
endometrioid endometrial cancer were enrolled in all further analysis. Student's t-test, Cox
regression analysis and Kaplan-Meier analysis were used were appropriate.
Results: Presence/absence of a postmenopausal bleeding was not associated with tumor stage (p
= 0.2) and age at diagnosis (p = 0.5). Asymptomatic patients with endometrial cancer had a
significantly higher rate of well and moderate-differentiated tumors compared to symptomatic
patients (p = 0.008). In univariable and multivariable survival analysis, tumor stage, tumor grade, and
patients' age at diagnosis, but not presence/absence of a postmenopausal bleeding, were associated
with disease free and overall survival.
Conclusion:  Asymptomatic patients with endometrial cancer have a higher rate of well
differentiated tumors compared to patients with a postmenopausal bleeding prior to diagnosis. The
prognosis of both groups of patients was similar.
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Background
Endometrial cancer is the most common gynecological
malignancy in developed countries with an estimated
39,000 newly diagnosed cases in the United States in
2007. Although many patients are diagnosed with an
early stage disease, 7400 deaths will occur [1].
Approximately 90% of women with endometrial cancer
have abnormal uterine bleeding as the only presenting
complaint leading to the diagnosis of the disease [2]. To
date, there is no consensus on the utility of screening pro-
cedures for the early detection of endometrial cancer [3-
8]. It has been suggested that screening of asymptomatic
endometrial cancer by transvaginal ultrasound before the
onset of clinical symptoms, i.e., postmenopausal bleed-
ing, leads to an earlier diagnosis [8]. As in other malignan-
cies, it can be hypothesized that an earlier diagnosis leads
to a lower stage of disease, a less radical surgery, a therapy
with less side effects and, subsequently, a better prognosis
of affected patients.
Interestingly, relatively few studies are available investi-
gating whether asymptomatic patients with endometrial
cancer have a better prognosis than those detected after
the onset of a postmenopausal bleeding. Gerber et al. per-
formed a retrospective study in 190 postmenopausal
patients with symptomatic endometrial cancer and 16
asymptomatic patients showing no difference in survival
in this relatively small series [7]. Osmer et al. compared 61
and 22 postmenopausal women with symptomatic and
asymptomatic endometrial cancer, respectively. Patients
with asymptomatic endometrial cancers showed a less
myometrial tumor infiltration and more well differenti-
ated tumors than symptomatic patients. A better progno-
sis for asymptomatic patients has been suggested [8].
Kimura et al. reviewed a total of 304 endometrial cancer
patients [9]. Patients diagnosed with asymptomatic
endometrial cancer showed a significantly better 5-year
overall survival rate than the patients diagnosed after the
onset of postmenopausal bleeding. The distribution of
clinical stages and histological grades did not differ
between both groups.
The aim of the present study was to estimate whether
asymptomatic patients with endometrial cancer have a
better prognosis than symptomatic patients with endome-
trial cancer diagnosed after postmenopausal bleeding in a
large series of postmenopausal patients with endometrial
cancer in a multi-center study.
Methods
Patients
Clinical data were obtained retrospectively from files at
the Medical University of Vienna, Department of Obstet-
rics and Gynecology, the Landeskrankenhaus Klagenfurt,
Department of Obstetrics and Gynecology, and the Inns-
bruck Medical University, Department of Obstetrics and
Gynecology. Six hundred five consecutive patients (Medi-
cal University of Vienna: n = 388, Landeskrankenhaus Kla-
genfurt: n = 79, Innsbruck Medical University: n = 138)
with histological confirmed endometrial cancer undergo-
ing surgery between December 1995 and January 2005
were included in our study. Five hundred forty three
patients with endometrioid endometrial cancer were
enrolled in all further analysis. Other histological sub-
types were excluded from further analysis.
Based on patients' history and on the clinical examination
performed by the referring physician and at time of refer-
ral to hospital, patients were classified into two groups
according to presence (symptomatic patients) or absence
(asymptomatic patients) of postmenopausal bleeding.
Asymptomatic patients were defined as neglecting a type
of bleeding in the previous 12 months, as having no signs
of bleeding seen during the gynecological examination
performed by the referring physician and at time of refer-
ral to hospital, and as not having any other symptoms
indicative for endometrial cancer. Patients' personal his-
tory has been performed in the participating study centers
in a standardized way. One of the most important ques-
tions was presence/absence of postmenopausal bleeding.
This has been clearly documented in all patients' files.
Clinical management
A guideline by the Austrian Society of Gynecology and
Obstetrics (OEGGG) and the Austrian Society of Gyneco-
logic Oncology (AGO) recommends endometrial sam-
pling in cases of a postmenopausal bleeding or an
endometrial thickness > 11 mm in asymptomatic women
[10]. Asymptomatic women included in our study are real
asymptomatic cases detected by "quasi-screening" and did
not seek care for other reasons. Diagnosis of endometrial
cancer was established by hysteroscopy, dilatation and
curettage. Subsequently, patients were treated by hysterec-
tomy, bilateral salping-oophorectomy, pelvic and in
selected cases paraaortic lymphadenectomy. In cases of
lymph node metastases, postoperative radiotherapy was
applied according to standardized treatment protocols.
Histological staging and grading was performed according
to the current International Federation of Gynecology and
Obstetrics (FIGO) classification on basis of the final path-
ologic evaluation of hysterectomy specimen.
Patients were followed up in regular intervals after sur-
gery, including inspection, vagino-rectal and screening for
serum tumor marker evaluation. In cases of clinically sus-
picious findings and/or tumor marker elevation com-
puted tomography was performed. The same protocols for
treatment and follow-up were used in all participating
centers.BMC Cancer 2009, 9:460 http://www.biomedcentral.com/1471-2407/9/460
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Statistical analysis
Values are given as means (standard deviation [SD]) for
evenly distributed values. Metric parameters were com-
pared using Student's t-test. All data a Student's t-test was
used for, were normally distributed. Nominal parameters
were compared using Chi square test. Survival probabili-
ties were calculated by a univariable Cox regression anal-
ysis (metric variables) or a product limit method of
Kaplan and Meier using the log-rank test (categorical var-
iables). A multivariable Cox regression model was per-
formed comprising tumor stage (FIGO I vs. FIGO II vs.
FIGO III vs. FIGO IV), tumor grade (G1 vs. G2 vs. G3), age
at diagnosis, and presence/absence of irregular bleeding.
The results were analyzed for the endpoint of disease-free
and overall survival. Survival times of patients disease-free
or still alive were censored with the last follow-up date.
The proportional hazards assumption has been checked
and found not to be violated. P-values of < 0.05 were con-
sidered statistically significant. We used the statistical soft-
ware SPSS 11.0 for Windows (SPSS 11.0, SPSS Inc.,
Chicago, IL) for statistical analysis.
Institutional review board
The present study was approved by our institutional
review board, the Ethics-Committee of the Medical Uni-
versity of Vienna and the Vienna General Hospital - AKH.
Results
Patients' characteristics of asymptomatic/symptomatic
patients with endometrial cancer are shown in Table 1.
Asymptomatic patients with endometrial cancer had a sig-
nificantly higher rate of well differentiated tumors. FIGO
tumor stages and patients' age were evenly distributed. In
univariable and multivariable survival analysis, tumor
stage, tumor grade, and patients' age at diagnosis were
associated with disease free and overall survival (Table 2,
Table 3). In a multivariable survival analysis presence/
absence of a postmenopausal bleeding prior to diagnosis
Table 1: Patients' characteristics.
Parameter Asymptomatic patients (No.[%]) Symptomatic patients (No. [%]) P
Number of patients 149 456
Patients with endometrioid endometrial cancer 133 410
Age at first diagnosis (years SD ) 66.3 (10.3) 67.1 (11.2) 0.9*
Tumor stage 0.07†
I 100 (75.2) 286 (69.8)
II 9 (6.8) 40 (9.8)
III 15 (11.2) 71 (17.2)
IV 9 (6.8) 13 (3.2)
Tumor grade 0.006†
G1 74 (55.7) 170 (41.5)
G2 45 (33.8) 153 (37.3)
G3 14 (10.5) 87 (21.2)
Patients with follow-up information available 133 409
Time of follow-up (months [SD]) 23.7 (24.03) 28.5 (25.76) 0.06*
Recurrence status
Patients with recurrent disease 14 (10.5) 55 (13.4) 0.2†
Time to recurrent disease (months [SD]) 18.5 (16.9) 20.4 (17.6) 0.7*
Status at last observation 0.7†
Alive with no evidence of disease 115 (86.5) 341 (83.4)
Stable disease 0 3 (0.7)
Progressive disease 8 (6.0) 34 (8.3)
Dead as a result of disease 9 (6.8) 25 (6.1)
Dead as a result of other causes 1 (0.7) 6 (1.5)
SD = standard deviation, * two sided student's t-test, † Chi squared test
Table 2: Univariable survival analysis in patients with endometrial cancer.
Disease free survival Overall survival
HR (95% CI) P HR (95% CI) P
Tumor stage (FIGO I vs. II vs. III vs. IV) - < 0.001* - < 0.001*
Tumor grade (G1 vs. G2 vs. G3) - < 0.001* - < 0.001*
Age at diagnosis 1.03 (1.01-1.05) 0.003† 1.05 (1.03-1.08) < 0.001†
* Kaplan-Meier analysis, † univariable Cox-Regression model, HR (95% CI) = Hazard Ratio (95% Confidence Interval)BMC Cancer 2009, 9:460 http://www.biomedcentral.com/1471-2407/9/460
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was not associated with disease free or overall survival
(Table 3). Kaplan-Meier curves for the influence of pres-
ence/absence of a postmenopausal bleeding on disease-
free (Figure 1) and overall (Figure 2) survival are shown.
Discussion
We present data on the prognostic value of presence/
absence of a postmenopausal bleeding prior to diagnosis
in large series of patients with endometrial cancer in a
multi-center study. In parallel to previous studies [9], we
did not ascertain a significant difference in prognosis
between asymptomatic and symptomatic patients.
Screening for gynecological malignancies has been advo-
cated in order to diagnose diseases at earlier stage leading
to earlier treatment with less side-effects and better prog-
nosis [11]. To date, screening tools for endometrial cancer
have not been identified. Transvaginal ultrasound has
been suggested to detect endometrial cancer in an earlier
stage before the onset of clinically recognizable symptoms
[6]. Our study falls short of showing any statistically sig-
nificant difference in disease-free and overall survival of
affected patients.
Based on our study design we cannot extrapolate our
results to a real screening situation. Although having no
formally organized screening program in Austria, the
majority of postmenopausal women routinely see their
gynecologist once a year, i.e. opportunistic screening.
Besides the PAP smear, a transvaginal sonography is rou-
tinely performed during this examination. Based on the
currently available evidence [5], a guideline by the Aus-
trian Society of Gynecology and Obstetrics (OEGGG) and
the Austrian Society of Gynecologic Oncology (AGO) rec-
Table 3: Multivariable survival analysis in patients with endometrial cancer.
Disease free survival* Overall survival*
HR (95% CI) P HR (95% CI) P
Tumor stage (FIGO I vs. II vs. III vs. IV) 1.9 (1.5-2.5) < 0.001 2.2 (1.7-2.8) < 0.001
Tumor grade (G1 vs. G2 vs. G3) 1.8 (1.3-2.6) 0.001 1.6 (1.1-2.4) 0.008
Age at diagnosis 1.03 (1.01-1.06) 0.01 1.05 (1.03-1.08) < 0.001
Bleeding vs. non bleeding 0.9 (0.5-1.6) 0.7 0.8 (0.5-1.4) 0.4
* multivariable Cox-Regression model, HR (95% CI) = Hazard Ratio (95% Confidence Interval)
Disease free survival Figure 1
Disease free survival. Kaplan-Meier curve for disease free 
survival of asymptomatic and symptomatic patients with 
endometrioid endometrial cancer.
P=0.5 
Overall Survival Figure 2
Overall Survival. Kaplan-Meier curve for overall survival of 
asymptomatic and symptomatic patients with endometrioid 
endometrial cancer.
P=0.3 BMC Cancer 2009, 9:460 http://www.biomedcentral.com/1471-2407/9/460
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ommends endometrial sampling in cases of asympto-
matic women and an endometrial thickness > 11 mm
[10]. This might be the most likely reason for having only
3/4 of women with endometrial cancer presenting with
postmenopausal bleeding.
Of note, our study was not set out to evaluate the advan-
tages or disadvantages of a transvaginal ultrasound in the
screening of endometrial cancer. Studies demonstrating a
positive effect of performing routine endometrial cancer
screening on overall mortality would possibly have to
include hundreds of thousands of women based on the
relatively low incidence of the disease, the high rate of
symptomatic women in early stage disease, and the good
prognosis of affected women. Due to high costs and miss-
ing data on the reliability of TVS as screening tool for
endometrial cancer the realization of a study like this
would be hard to justify [12,13]. We speculate that such
large-scale studies will not be performed and completed
in the near future.
Our study supports previously published studies indicat-
ing that tumor biology in asymptomatic patients was dif-
ferent than in symptomatic patients [8]. This possibly
reflects a higher propensity of low-differentiated tumors
to cause postmenopausal bleeding than well/moderate
differentiated endometrial cancers.
Our study has strengths and weaknesses, namely the ret-
rospective study design, the extraction of information
from patients' files, the relatively low number of events
due to a generally good prognosis of affected patients, and
the relatively short time of follow up. Another interesting
point to mention is the relatively high percentage of
women having advanced FIGO stages, i.e., FIGO II-IV, and
still not having any symptoms. This can be easily
explained in patients with FIGO IIIA, but not for other
stages. Of note, we double-checked all FIGO stages and
found our numbers to be correct. This has to be consid-
ered when interpreting the results of our study.
Conclusion
To conclude, asymptomatic patients with endometrial
cancer undergoing surgery have a higher rate of well and
moderate differentiated tumors compared to patients
with a postmenopausal bleeding prior to diagnosis. The
prognosis of both groups of patients was similar.
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